Zylet is a topical anti-inflammatory corticosteroid and antibiotic combination for ophthalmic use. It is indicated for treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Topical ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in treating chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.
The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in Zylet (tobramycin) is active against a wide range of bacterial ocular pathogens, including staphylococci and streptococci, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus, and some Neisseria species.
Anti-inflammatory efficacy of Zylet can be attributed to its active component, loteprednol etabonate 0.5%. Levels of loteprednol etabonate in the aqueous humor were found to be comparable between Lotemax (loteprednol etabonate ophthalmic suspension 0.5%) and Zylet treatment groups in a controlled clinical study of ocular penetration.1